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The European Association for the Study of Obesity 
(EASO), in collaboration with the EASO European Coali-
tion for People Living with Obesity (ECPO), is committed 
to sharing knowledge, evidence-based recommendations, 
and guidance toward the clinical, patient, research, and 
policy communities. Since the beginning of the coronavi-
rus disease 2019 (COVID-19) pandemic, our mission has 
been to identify the particular needs of individuals living 
with obesity, healthcare providers, and policy makers [1].
Obesity, a complex chronic disease in which abnormal 
or excessive fat impairs health, is associated with in-
creased risks for the initiation, progression, and outcomes 
of COVID-19 [2]. Adults living with obesity are more 
likely to require acute care and admission to the intensive 
care unit, intubation, and mechanical ventilation, espe-
cially among those younger than 60 years [2–5]. Mortal-
ity from COVID-19 was found to be higher among pa-
tients with obesity in some studies [4, 5]. Obesity is also 
the most commonly reported underlying medical condi-
tion in US children presenting severe COVID-19 [6].
People living with obesity often have a systemic low-
grade inflammation, a higher susceptibility to infections, 
and a dampened immune response to infectious agents 
[7]. Obesity may also play a role in altering the viral life 
cycle, together with the intrinsic immunological pertur-
bations and associated impaired immune response, lead-
ing to more severe clinical outcomes as compared to in-
dividuals with normal body mass index (BMI). The pro-
longed viral clearance demonstrated in people with 
obesity infected with SARS-CoV-2 may support the rela-
tion between obesity and the risk of severe COVID-19. 
The positive correlation between body weight and time to 
negative detection of COVID-19 genes might suggest a 
larger viral load in people with obesity, while angiotensin-
converting enzyme 2 in adipose tissue might be a critical 
link between obesity, non-communicable diseases, and 
the susceptibility to and severity of COVID-19 [8].
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People living with obesity demonstrate an impaired 
immune response to influenza A virus (IAV) vaccination 
and antimicrobial treatment [9]. Hence, the efficacy of 
other vaccines might be reduced in this population. Al-
though data regarding the effectiveness of vaccination for 
COVID-19 in people with obesity is unavailable, it is 
known from studies regarding vaccination for IAV H1N1 
that host-associated factors such as obesity can reduce 
vaccine efficacy [10]. Higher BMI was associated with a 
greater decline in influenza A antibody titers after 12 
months, suggesting that obesity may impair the ability to 
mount a protective immune response to influenza virus 
[11]. The relatively lower effectiveness of influenza vac-
cines in people with obesity is hypothesized to be medi-
ated by insufficient T cell function, since peripheral blood 
mononuclear cells from vaccinated adults with obesity 
show decreased activation of cytotoxic T cells and re-
duced expression of functional markers [10]. 
Subgroup analysis in COVID-19 vaccination trials 
demonstrated that the efficacy among adults with obesity 
was, in the short term, generally consistent with that ob-
served in the overall population [12]. A recent random-
ized trial, which estimated vaccine efficacy in the short-
term, for patients with obesity and other coexisting con-
ditions such as hypertension found effectiveness to be 
slightly lower among those with higher numbers of coex-
isting conditions [13]. Therefore, we conclude that peo-
ple living with obesity should be encouraged to be vacci-
nated against COVID-19, and prioritized, similar to oth-
er populations at risk of severe outcomes due to 
preconditions, such as diabetes mellitus, chronic cardio-
vascular disease or respiratory disease, immunocompro-
mised states, or cancers. In children, ongoing studies are 
currently investigating the efficacy and safety of CO-
VID-19 vaccines. Accordingly, we are calling for:
 − Considering people living with obesity as at-risk of se-
vere COVID-19;
 − Prioritizing people with obesity for COVID-19 vacci-
nation;
 − Promoting studies that will examine the long-term ef-
ficacy of COVID-19 vaccination on neutralizing anti-
body levels and the infection rate in children, adoles-
cents, and adults with obesity. 
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